ViroPharma Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Exton PA United States (1994)
Status: Acquired by Shire (2014) → now Takeda (2018)

Organization Overview

First Clinical Trial
2006
NCT00314054
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ViroPharma Incorporated

Active Ingredients

Drugs in Phase 4 Trials (1)

C1 Esterase Inhibitor (Human) (Cinryze) (5 trials)

Drugs in Phase 3 Trials (3)

Key: ViroPharma (2) Acquired (1)

ganciclovir (cytovene) (1 trial)

maribavir (Livtencity) (3 trials)

urea (1 trial)

Drugs in Phase 2 Trials (4)

interferon alpha-2b (Intron-A) (1 trial)

nesbuvir (4 trials)

ribavirin (virazole) (1 trial)

vp20621 (1 trial)

Drugs in Phase 1 Trials (2)

desipramine (pertofrane) (1 trial)

vp 20629 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Angioedema (Phase 4)

Angioedemas, Hereditary (Phase 4)

Ataxia (Phase 1)

Cerebellar Ataxia (Phase 1)

Clostridium Infections (Phase 2)

Communicable Diseases (Phase 2)

Cytomegalovirus Infections (Phase 3)

Friedreich Ataxia (Phase 1)

Hepatic Insufficiency (Phase 1)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Infections (Phase 2)

Liver Failure (Phase 1)

Neuromyelitis Optica (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial APIs: 10